Aratana Gets Rights To Two Compounds For Animal Use

Posted: March 4, 2011, 5:25 p.m., EDT



Published:

Aratana Therapeutics Inc. of Kansas City, Kan., reported today that it has entered into a license agreement with RaQualia Pharma Inc. to develop two compounds from RaQualia’s human clinical development portfolio for companion animal use.

As part of the agreement, Aratana will be granted global rights for development and commercialization of the licensed animal health products. In exchange, the Japanese company will receive upfront payment, development milestones and royalties on global sales.

The first compound is a selective EP-4 antagonist. Aratana reported that the compound has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for several conditions including, pain, cancer and autoimmune/inflammatory diseases.

The second compound, a selective Ghrelin agonist, has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for treatment of cachexia and frailty, according to Aratana.

Aratana announced its entry into the animal health industry in early January, which was jump-started by $20 million in Series A financing.


Related story: Aratana Enters Animal Health Industry with $20 Million in Funding

 

 

<Home>

Edit Module
Edit ModuleShow Tags

Archive »Read More

Learn at Your Leisure About Pet Nutrition

The Hill’s Virtual Event Center is available online through June 30.

UC Davis Establishes Fund to Aid California K-9 Officers

The Faithful Partner Fund is initially funded by matching $25,000 contributions from both the U.C. Davis School of Veterinary Medicine and the U.C. Davis Police Department.

Study Confirms Benefits of Pedicle Tie Spays

Compared to PDL, PT procedures are safe and reduce a patient’s anesthesia time.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module